Abstract
Aim: There are sound reasons for considering the use of long-acting injectable antipsychotics early in the course of schizophrenia. We reviewed available literature on the subject.
Method: We conducted an electronic database search and critically reviewed all studies in which a long-acting injectable antipsychotic was evaluated in early psychosis patients.
Results: There is a need for well-designed studies as most of those reported were open-label and non-comparative, and samples were frequently small.
Conclusions: The available evidence does suggest that long-acting injectable antipsychotics can be used safely and effectively in early stages of the illness, and that they may be associated with better outcomes than with oral medications. However, this is largely supported by evidence from naturalistic cohort studies and a small number of controlled trials of risperidone long-acting injection. Evidence for olanzapine and paliperidone longacting injectables in particular is limited.
| Original language | English |
|---|---|
| Pages (from-to) | 247-254 |
| Number of pages | 8 |
| Journal | Early Intervention in Psychiatry |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Aug 2013 |
Keywords
- depot
- early psychosis
- long-acting antipsychotic
- schizophrenia
- OPEN-LABEL TRIAL
- 1ST-EPISODE SCHIZOPHRENIA
- PRODROMAL SIGNS
- 1ST EPISODE
- RISPERIDONE
- DISORDERS
- REMISSION
- INJECTION
- VULNERABILITY
- MEDICATION